Table 1 Patient demographic and clinical characteristics.
Variable | Loncastuximab line of therapy | |
|---|---|---|
3rd Line N = 95 (%) | 4th Line N = 23 (%) | |
Age, median (Q1, Q3), years | 66 (61, 72) | 57 (50, 64) |
Male | 58 (61%) | 10 (43%) |
Race | ||
White | 58 (61%) | 15 (65%) |
African American | 31 (33%) | 6 (26%) |
American Indian or Alaska Native | 1 (1%) | 0 (0%) |
Asian | 5 (5%) | 2 (9%) |
Hispanic/Latin/Spanish origin | ||
Yes | 7 (7%) | 3 (13%) |
No | 86 (91%) | 13 (57%) |
Unknown | 2 (2%) | 7 (30%) |
Type of DLBCL diagnosis | ||
De novo DLBCL | 44 (46%) | 21 (91%) |
DLBCL arising from low-grade lymphoma | 32 (34%) | 1 (4%) |
High-grade B-cell lymphoma | 19 (20%) | 1 (4%) |
Cell of origin | ||
Germinal center B-cell (GCB) | 48 (51%) | 16 (70%) |
Activated B-cell (ABC) | 28 (29%) | 3 (13%) |
Unknown | 19 (20%) | 4 (17%) |
DHL/THL | 31 (33%) | 3 (13%) |
DEL/TEL | 36 (37%) | 15 (65%) |
Ann Arbor Stage | ||
Stage I | 12 (13%) | 0 (0%) |
Stage II | 10 (11%) | 3 (13%) |
Stage III | 24 (25%) | 7 (30%) |
Stage IV | 49 (52%) | 13 (57%) |
Presence of bulky diseasea | ||
Yes | 24 (25%) | 2 (9%) |
No | 69 (73%) | 21 (91%) |
Unknown | 2 (2%) | 0 (0%) |
IPI risk groups | ||
Low risk | 14 (15%) | 4 (17%) |
Low-intermediate risk | 19 (20%) | 14 (61%) |
High-intermediate risk | 20 (21%) | 5 (22%) |
High risk | 42 (44%) | 0 (0%) |
Comorbidities | ||
None | 29 (31%) | 13 (57%) |
Diabetes (without complication) | 34 (36%) | 4 (17%) |
Chronic pulmonary disease | 21 (22%) | 2 (9%) |
Peripheral vascular disease | 14 (15%) | 3 (13%) |
Congestive heart failure | 13 (14%) | 2 (9%) |
Diabetes without end organ damage | 11 (12%) | 1 (4%) |
Myocardial infarction | 11 (12%) | 2 (9%) |
Mild liver disease | 11 (12%) | 2 (9%) |
Cerebrovascular disease (except hemiplegia) | 9 (9%) | 1 (4%) |
Ulcer disease | 6 (6%) | 1 (4%) |
Connective tissue disease | 2 (2%) | 1 (4%) |
Second solid tumor (non-metastatic) | 4 (4%) | 0 (0%) |
Moderate or severe liver disease | 2 (2%) | 0 (0%) |
Other | 2 (2%) | 0 (0%) |
